Clean Cells and Naobios, both part of the Clean Biologics group, will participate in BIO KOREA 2026 from April 28–30 at COEX, Seoul, as the companies deepen their strategic expansion into Asia’s fast-growing biologics, vaccines and cell and gene therapy markets. 

The event marks a significant push into South Korea’s rapidly expanding bio-health ecosystem, where the companies plan to showcase an integrated European CRO-CDMO model combining GMP manufacturing and quality control for virus-based products.

Clean Cells is targeting South Korea’s emergence as a major cell and gene therapy and vaccine manufacturing hub, with the local CGT manufacturing market projected to reach $1.5 billion by 2030. The company’s portfolio spans GMP quality control, viral safety and identity testing, genetic stability, purity testing and replication-competent particle detection, supporting biologics and ATMP developers seeking global regulatory approvals.

With over 25 years of experience, Clean Cells supports the full development pathway from early R&D through commercial GMP stages, covering viral products, cell and gene therapies, vaccines, monoclonal antibodies and recombinant proteins.

Meanwhile, Naobios will spotlight its GMP clinical batch manufacturing capabilities for viral vaccines, oncolytic viruses, viral vectors and exosomes, backed by BSL2 and BSL3-certified facilities and bioreactors up to 200 litres. The CDMO supports programmes from proof-of-concept and Phase 3 through commercial manufacturing, with end-to-end upstream, downstream and final drug product expertise. 

The company already has an established track record in the Asian market, including collaborations in South Korea on HIV vaccine industrial production and in Japan on a live-attenuated mpox vaccine programme, alongside partnerships in the U.S. ecosystem.